




FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 1430/13		Serial No. 10/613,262	
List of Documents Cited by Applicant							
				Applicant(s): Gilboa et al.			
				Filing Date: July 3, 2003		Group 1633	
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes   No	
/AW/	A	WO99/45018 A	09/10/1999	WIPO	Hicklin et al.		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
Examiner Initial							
/AW/	B	Supplementary Partial European Search Report corresponding to an EP Patent Application No. 03763158 dated April 3, 2007					
/AW/	C	Gabrilovich et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clinical Cancer Research, Vol. 5, (1999), pp.2963-2970					
/AW/	D	Nair et al. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood, Vol. 102, No. 3, (2003), pp.964-971					

EXAMINER /Anne Marie Wehbe/ (09/01/2007) DATE CONSIDERED 09/01/2007

\*Examiner/Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 1430/13	Serial No. 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing date if Appropriate

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Name of Patentee or Applicant	Translation Yes   No

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

Examiner Initial		
/AW/	A	BACHMANN et al. <i>Protection Against Immunopathological Consequences of a Viral Infection by Activated but not Resting Cytotoxic T Cells: T Cell Memory Without "Memory T Cells"</i> <i>Proceedings of The National Academy of Sciences USA</i> , Vol. 94, (1997), pp. 640-645
/AW/	B	BAILAR III et al. <i>Cancer Undefeated</i> <i>The New England Journal of Medicine</i> , Vol. 336, No. 22, (1997), pp. 1569-1574
/AW/	C	BLANCHER et al. <i>The Molecular Basis of the Hypoxia Response Pathway: Tumour Hypoxia as a Therapy Target</i> <i>Cancer and Metastasis Review</i> , Vol. 17, (1998), pp. 187-194

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> Patent and Trademark Office		<b>Attorney Docket No.</b> 1430/13	<b>Serial No.</b> 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633
/AW/	D	BOCZKOWSKI et al. <i>Dendritic Cells Pulsed with RNA are Potent Antigen-Presenting Cells in Vitro and in Vivo</i> <i>Journal of Experimental Medicine</i> , Vol. 184, (1996), pp. 465-472	
	E	BROSTJAN et al. <i>Monitoring of Circulating Angiogenic Factors in Dendritic Cell-Based Cancer Immunotherapy</i> <i>Cancer</i> , Vol. 98, No. 10, (2003), pp. 2291-2301	
	F	CHENG et al. <i>Tumor-Specific Immunity and Antiangiogenesis Generated by a DNA Vaccine Encoding Calreticulin Linked to a Tumor Antigen</i> <i>The Journal of Clinical Investigation</i> , Vol. 108, No. 5, (200), pp. 669-678	
	G	CHERRINGTON et al. <i>New Paradigms for the Treatment of Cancer: The Role of Anti-Angiogenesis Agents</i> <i>Advances in Cancer Research</i> , Vol. 79, (2000), pp. 1-38	
	H	CRYSTAL, Ronald G. <i>In Vivo and Ex Vivo Gene Therapy Strategies to Treat Tumors Using Adenovirus Gene Transfer Vectors</i> <i>Cancer Chemother Pharmacol</i> , Vol. 43, (1999), pp. S90-S99	
	I	DEPLANQUE et al. <i>Anti-Angiogenic Agents: Clinical Trial Design and Therapies in Development</i> <i>European Journal of Cancer</i> , Vol. 36, (2000), pp. 1713-1724	
	J	EATOCK et al. <i>Tumour Vasculature as a Target for Anticancer Therapy</i> <i>Cancer Treatment Reviews</i> , Vol. 26, (2000), pp. 191-204	
	K	GABRILOVICH et al. <i>Production of Vascular Endothelial Growth Factor by Human Tumors Inhibits the Functional Maturation of Dendritic Cells</i> <i>Nature Medicine</i> , Vol. 2, No. 10, October (1996), pp. 1096-1103	
	L	GALE et al. <i>Growth Factors Acting Via Endothelial Cell-Specific Receptor Tyrosine Kinases: VEGFs, Angiopoietins, and Ephrins in Vascular Development</i> <i>Genes &amp; Development</i> , Vol. 13, (1999), pp. 1055-1066	
	M	GILBOA, Eli. <i>The Makings of a Tumor Rejection Antigen</i> <i>Immunity</i> , Vol. 11, (1999), pp. 263-270	

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*Examiner/Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> Patent and Trademark Office		<b>Attorney Docket No.</b> 1430/13	<b>Serial No.</b> 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633
/AW/	N	HANAHAH, Douglas. <i>Signaling Vascular Morphogenesis and Maintenance Science</i> , Vol. 277, (1997), pp. 48-50	
	O	HANAHAH et al. <i>Patterns and Emerging Mechanisms of the Angiogenic Switch During Tumorigenesis Cell</i> , Vol.86, August 9, (1996), pp. 353-364	
	P	HEISER et al. <i>Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses in Vitro The Journal of Immunology</i> , Vol. 164, (2000), pp. 5508-5514	
	Q	KERBEL, Robert S. <i>A Cancer Therapy Resistant to Resistance Nature</i> , Vol. 390, (1997), pp. 335-336	
	R	LANGE-ASSCHENFELDT et al. <i>The Angiogenesis Inhibitor Vasostatin Does not Impair Wound Healing at Tumor-Inhibiting Doses Journal of Investigative Dermatology</i> , Vol. 117, (2001), pp. 1036-1041	
	S	LI et al. <i>Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis Journal of Experimental Medicine</i> , Vol. 195, No. 12, (2002), pp. 1575-1584	
	T	LIN et al. <i>Antiangiogenic Gene Therapy Targeting the Endothelium-Specific Receptor Tyrosine Kinase Tie2 Proceedings of the National Academy of Sciences USA</i> , Vol. 95, (1998), pp. 8829-8834	
	U	LIN et al. <i>Inhibition of Tumor Angiogenesis Using a Soluble Receptor Establishes a Role for Tie2 in Pathologic Vascular Growth Journal of Clinical Investigation</i> , Vol. 100, No. 8, (1997), pp. 2072-2078	
↓	V	MINEV et al. <i>Cytotoxic T Cell Immunity Against Telomerase Reverse Transcriptase in Humans Proceedings of the National Academy of Sciences USA</i> , Vol. 97, No. 9, (2000), pp. 4796-4801	

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449 U.S. Department of Commerce</b> Patent and Trademark Office		<b>Attorney Docket No.</b> 1430/13	<b>Serial No.</b> 10/613,262
List of Documents Cited by Applicant			
		Applicant(s): Gilboa et al.	
		Filing Date: July 3, 2003	Group 1633
/AW/	W	NAIR et al. <i>Induction of Primary Carcinoembryonic Antigen (CEA)-specific Cytotoxic T Lymphocytes in Vitro Using Human Dendritic Cells Transfected with RNA</i> <i>Nature Biotechnology</i> , Vol. 16, (1998), pp. 364-369	
	X	NAIR et al. <i>RNA-Transfected Dendritic Cells</i> <i>Expert Review of Vaccines</i> , Vol. 1, No. 4, (2002), pp. 507-513	
	Y	NAIR et al. <i>Induction of Cytotoxic T Cell Responses and Tumor Immunity Against Unrelated Tumors Using Telomerase Reverse Transcriptase RNA Transfected Dendritic Cells</i> <i>Nature Medicine</i> , Vol. 6, No. 8, (2000), pp. 1011-1017	
	Z	NIETHAMMER et al. <i>A DNA Vaccine Against VEGF Receptor 2 Prevents Effective Angiogenesis and Inhibits Tumor Growth</i> <i>Nature Medicine</i> , Vol. 8, No. 12, (2002), pp. 1369-1375	
	AA	PARDOLL, Drew M. <i>Cancer Vaccines</i> <i>Nature Medicine Vaccine Supplement</i> , Vol. 4, No. 5, (1998), pp. 525-531	
	AB	QUINN et al. <i>CM101, a Polysaccharide Antitumor Agent, Does Not Inhibit Wound Healing in Murine Models</i> <i>Journal of Cancer Research and Clinical Oncology</i> , Volume 121, (1995), pp. 253-356	
	AC	ROSENBERG, Steven A. <i>Progress in Human Tumour Immunology and Immunotherapy</i> <i>Nature</i> , Vol. 411, (2001), pp. 380-384	
	AD	SAEBOE-LARSEN et al. <i>mRNA-based Electroporation of Human Dendritic Cells and Induction of Cytotoxic T Lymphocyte Responses Against the Telomerase Catalytic Subunit (hTERT)</i> <i>Journal of Immunological Methods</i> , Vol. 259, (2002), pp. 191-203	
↓	AE	SCHREURS et al. <i>Dendritic Cells Break Tolerance and Induce Protective Immunity Against a Melanocyte Differentiation Antigen in an Autologous Melanoma Model</i> <i>Cancer Research</i> , Vol. 60, (2000), pp. 6995-7001	

EXAMINER /Anne Marie Wehbel/ (09/01/2007) DATE CONSIDERED 09/01/2007

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office		<b>Attorney Docket No.</b> 1430/13	<b>Serial No.</b> 10/613,262
List of Documents Cited by Applicant			
		<b>Applicant(s):</b> Gilboa et al.	
		<b>Filing Date:</b> July 3, 2003	<b>Group</b> 1633
	AF	SIEMEISTER et al. <i>Two Independent Mechanisms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering with Either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway</i> <i>Cancer Research</i> , Vol. 59, (1999), pp. 3185-3191	
	AG	VEIKKOLA et al. <i>VEGFs, Receptors and Angiogenesis</i> <i>Seminars in Cancer Biology</i> , Vol. 9, (1999), pp. 211-220	
	AH	VONDERHEIDE et al. <i>The Telomerase Catalytic Subunit is a Widely Expressed Tumor-Associated Antigen Recognized by Cytotoxic T Lymphocytes</i> <i>Immunity</i> , Vol. 10, (1999), pp. 673-679	

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.